Thread by @LancetGastroHep

In part 2 of the #ALD #NASH SIG, Stephen Harrison covers #NASH therapeutics and MoAs #TLM22

@juanpabloarab now covers the therapy landscape for alcohol-associated hepatitis - steroids suboptimal with benefits beyond 1 month limited #TLM22

In the US, lack of response indicates a huge unmet need - @juanpabloarab #TLM22

Early promise from #FMT in small studies for improving both liver disease and AUD and cravings; phages might also play a role, from proof-of-concept study #TLM22

Adding antibiotic regimen to steroids did not improve survival in ~240pt Antibiocor trial, presented last year - a growing number of other promising targets but none close to approval #TLM22

Ashwani Singal now discusses issues around selecting for patients with AUD and liver disease for LTx #TLM22

Singal highlights the QuickTrans study from the Lille group on early liver transplantation, which attempted a more objective LTx selection approach thelancet.com/journals/langa… #TLM22